Journal List > Lab Anim Res > v.26(3) > 1053618

TOOLS
Lee, Hong, Oh, Park, Kim, Park, Jeong, and Kim: Antibacterial Activity of Sanguisorba officinalis against Helicobacter pylori
Original Article

Lab. Anim. Res. 2010;26(3):257-263.

Published online: 17 September 2010

DOI: https://doi.org/10.5625/lar.2010.26.3.257

Antibacterial Activity of Sanguisorba officinalis against Helicobacter pylori

Hyun-A Lee1, Sunhwa Hong1, Hong-Geun Oh2, Sang-Ho Park3, Youn-Chul Kim4, Hyun Park5, Gil-Saeng Jeong5, Okjin Kim1, 6, ∗

1Center for Animal Resources Development, Wonkwang University, Iksan, Korea

2Huvet Co. Ltd, Iksan, Korea

3Korea DNA Valley Co. Ltd, Iksan, Korea

4College of Pharmacy, Wonkwang University, Iksan, Korea

5Zoonosis Research Center, Wonkwang University, Iksan, Korea

6Institute of Animal Experiment & Efficacy Evaluattion, Wonkwang University, Iksan, Korea

∗Corresponding author: Okjin Kim, Center for Animal Resources Development, Wonkwang University, 344-2 Shinyoung-dong, Iksan, Jeonbuk 570-749, Korea Tel: +82-63-850-6668 Fax: +82-63-850-7308 E-mail: kimoj@wku.ac.kr

Received 25 February 2010       Revised 21 July 2010       Accepted 2 September 2010

Copyright © 2010 Korean Association for Laboratory Animal Science

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

In this study, a medicinal herbal plant, Sanguisorba officinalis, was examined and screened for anti-Helicobacter pylori (H. pylori) activity. Seventy percent ethanol was used for herbal extraction. For anti-H. pylori activity screening, inhibitory zone tests as an in vitro assay and in vivo study using a Mongolian gerbil (Meriones unguiculatus) model were performed. Also, the safety of herbal compounds was evaluated by animal study. As a result of inhibitory zone test, Sanguisorba officinalis extract demonstrated strong anti-H. pylori activities. Also, as results of in vivo animal studies, Sanguisorba officinalis extract demonstrated strong therapeutic effects against H. pylori infection according to the criteria of histological examination and rapid urease test. As results of the safety study, after 28 days treatment of the Sanguisorba officinalis extract, the animals were not detected any grossly and histological changes. These results demonstrate that it can be successfully cured against H. pylori infection and protected from H. pylori-induced pathology with Sanguisorba officinalis extract. It could be a promising candidate herb treatment for patients with gastric complaints including gastric ulcer caused by H. pylori.

Keywords: Sanguisorba officinalis, Helicobacter pylori, antibacterial activity, herb, therapy

REFERENCES

An B. J.., Lee J. T.., Lee S. A.., Kwak J. H.., Park J. M.., Lee J. Y.., Son J. H.2004. Antioxidant effects and application as natural ingredients of Korean Sanguisorbae officinalis L. J. Korean Soc. Appl. Biol. Chem. 47(2):244–250.
Ahn Y. O.., Park B. J.., Yoo K. Y.., Kim N. K.., Heo D. S.., Lee J. K.., Ahn H. S.., Kang D. H.., Kim H.., Lee M.S.., Park T.S.1991. Incidence estimation of stomach cancer among Koreans. J. Kor. Med. Sci. 6:7–14.
crossref
Bastow K. F.., Bori I. D.., Fukushima Y.., Kashiwada Y.., Tanaka T.., Nonaka G.., Nishioka I.., Lee K.-H.1993. Inhibition of DNA Topoisomerases by sanguiin H-6, a cytotoxic dimeric ellagitannin from Sanguisorba officinalis. Planta Med. 59:240–245.
Han D.S.2007. Treatment of H. pylori infection and current status of vaccine development. Hanyang Med. Rev. 27:81–95.
Hansson L. E.., Nyren O.., Hsing A. W.., Bergstrom R.., Josefsson S.., Chow W. H.., Fraumeni J. F.., Adami H.O.1996. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N. Engl. J. Med. 355:242–249.
crossref
Harris A.1997. Treatment of Helicobacter pylori. Drugs Today. 33:59–66.
Honda S.., Fujioka T.., Tokieda M.., Satoh R.., Nishizono A.., Nasu M.1998. Development of Helicobacter pylori induced-gastric carcinoma in Mongolian gerbils. Cancer Res. 58:4255–4259.
Jung T. S.., Kang S. C.., Choi Y. J.., Jeon B. S.., Park J. W.., Jung S. A.., Song J. Y.., Choi S. H.., Park S. G.., Choe M. Y.., Lee B. S.., Byun E. Y.., Baik S. C.., Lee W. K.., Cho M. J.., Youn H. S.., Ko G. H.., Rhee K. H.2000. Two-dimensional gel electrophoresis of Helicobacter pylori for proteomic analysis. J. Korean Soc. Microbiol. 35:97–108.
Kim B. W.., Choi M. G.., Choi H.., Moon S. B.., Kim B. K.., Chae H. S.., Kim J. K.., Chung I. S.., Chung K. W.., Sun H. S.., Park D.H.1999. Pooled analysis of antibiotic therapy for Helicobacter pylori eradication in Korea. Korean J. Gastroenterol. 34:42–49.
Kim J. M.2007. Antibiotic resistance in Helicobacter pylori. Hanyang Med. Rev. 27:80–95.
Kim J. M.., Kim J. S.., Jung H. C.., Kim N.., Kim Y. J.., Song I. S.2004. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob. Agents Chemother. 48:4843–4847.
Kim S. H.., Kim O. J.2004. Application of consensus polymerase chain reaction for monitoring of Helicobacter species. Lab. Animal. Res. 20:316–320.
Koehn F. E.., Carter G. T.2005. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 4:206–220.
crossref
Lee J.., Kim S. M.., Im E. H.., Choi Y. W.., Kim Y. M.., Kim P. S.., Lee J. H.2005. The prevalence of antimicrobial resistance in Helicobacter pylori isolated in Daejeon. Korean J. Clin. Microbiol. 8:47–50.
Lee J. Y.., Kim W.., Gawk G. Y.., Park S. C.., Ye B. D.., Lee S. H.., Kim S. G.., Kim J. S.., Jun H. C.., Song I. S.2002. Reinfection rate and clinical manifestation of Helicobacter pylori-positive peptic ulcer disease after triple therapy containing clarithromycin. Korean J. Gastrornterol. 39:93–100.
Lim T. H.., Lee J. M.., Cha B. J.2002. Antifungal activity and identification of an Actinomycetes straun isolated from mummified peaches. Kor. J. Appl. Microbiol. Biotechnol. 28:161–166.
Marshall B. J.., Warren J. R.1984. Unidentified curved bacilli in the stomach of patients with gastric and peptic ulceration. Lancet. 1:1311–1315.
Nguyen T.T.., Cho S.O.., Ban J.Y.., Kim J.Y.., Ju H.S.., Koh S.B.., Song K.S.., Seong Y.H.2008. Neuroprotective effect of Sanguisorbae radix against oxidative stress-induced brain damage: in vitro and in vivo. Biol. Pharm. Bull. 31(11):2028–2035.
crossref
Park H. J.., Kim J. W.., Lee J. H.., Shin J. H.., Yu K. A.2000. Detection of clarithromycin resistant Helicobacter pylori by polymerase chain reaction. Korean J. Gastroenterol. 47:459–461.
Park K.H.., Koh D.., Kim K.., Park J.., Lim Y.2004. Antiallergic activity of a disaccharide isolated from Sanguisorba officinalis. Phytother. Res. 18(8):658–662.
Reher G.., Budesinsky M.1992. Triterpenoids from plants of the anguissorbeae. Phytochemistry. 31:3909–3914.
Shim S. G.., Kim J. J.., Kim Y. H.., Sung I. K.., Son H. J.., Lee K. T.., Rhee P. L.., Koh K. C.., Paik S. W.., Rhee J. C.., Choi K. W.., Kim C. S.., Choi M. S.., Ryu K. H.., Lee, H. Y. Heo J. S.., Noh J.H.2000. One-week triple therapy for Helicobacter pylori a prospective, randomized study. Korean J. Gastroenterol. 35:16–22.
Tanaka T.., Nonaka G.., Nishioka I.1983. 7-O-Galloyl-(+)catechin and 3-O-galloylprocyanidin B-3 from Sanguisorba officinalis. Phytochemistry. 22:2575–2578.
crossref
Velazquez M.., Feirtag J. M.1999. Helicobacter pylori: characteristics, pathogenicity, detection methods and mode of transmission implicating foods and water. Int. J. Microbiol. 53:95–104.
53, 95-104. Wouden E.., Thijs J.., Zwet A.., Sluiter W.., Kleibeuker J.1999. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a metaanalysis. Am. J. Gastroenterol. 94:1751–1759.
Yam M.F.., Ang L.F.., Salman I.M.., Ameer O.Z.., Lim V.., Ong L.M.., Ahmad M.., Asmawil M.Z.., Basir R.2009. Orthosiphon stamineus leaf extract protects against ethanol-induced gastropathy in rats. J. Med. Food. 12(5):1089–1097.
crossref
Yokozawa T.., Chen C. P.., Tanaka T.., Kitani K.2000. A study on the nitric oxide production-suppressing activity of Sanguisorbae Radix components. Biol. Pharm. Bull. 23:717–722.
crossref

Figure 1.
Results of polymerase chin reaction in the study of anti-H. pylori activity with Sanguisorba officinalis extract. M: 100 bp marker, P: DNA from H. pylori ATCC 43504, N: negative control, 1~2: Group I (H. pylori+Sanguisorba officinalis), 3~6: Group II (H. pylori + phosphate-buffered saline).
lar-26-257f1.tif
Table 1.
Anti-H. pylori activities of Sanguisorba officinalis extract using the paper disk diffusion bioassay
Treatment Clear zone (mm)
6 hrs 12 hrs 24 hrs 48 hrs 60 hrs
Dimethyl sulfoxide 0 0 0 0 0
Gentamicin 6 9 7 7 7
Kanamycin 5 8 8 7 7
Enrofloxacin 9 13 13 12 9
Sanguisorba officinalis 100 (1.5 mg) 8 13 12 12 10
10-1 (0.15 mg) 4 6 6 5 5
Table 2.
Change in body weights (g) of mice treated with H. pylori and/or Sanguisorba officinalis extract in vivo study
Group Treatment Week after inoculation
0 1 2 3 4
I H. pylori+Sanguisorbaa 132.5± 2.0 136.0±2.1 140.0±2.1∗ 142.5±1.6∗ 144.0±1.1∗
II H. pylori+PBS 132.5±1.5 135.0±2.0 135.0±2.1 135.5±2.0 136.5±1.6
III PBS+Sanguisorba 133.0±2.1 138.0±2.1 142.0± 2.0∗ 144.5±2.0∗ 145.0±2.5∗
IV PBS+PBS 133.5±2.1 138.5±1.1 143.0±1.5∗ 145.0±2.0∗ 146.0±2.5∗

a Sanguisorba officinalis treatment was contuinued with 400 mg/kg dose during 4 weeks after Helicobacter pylori infection. PBS, phosphate-buffered saline.

∗ Significantly different from the positive control group II (P<0.05).

Table 3.
Gross and histopathological lesion scores of mice treated with H. pylori and/or Sanguisorba officinalis extract in vivo study
Group Treatment Gross lesion scores Histopathological lesion scores
I H. pylori+Sanguisorba 12.0±3.5∗ 2.0±0.50∗
II H. pylori+PBS 95.0±5.5 8.0±1.50
III PBS+Sanguisorba 0∗ 0∗
IV PBS+PBS 0∗ 0∗

PBS, phosphate-buffered saline.

∗ Significantly different from the positive control group II (P<0.05).

Table 4.
Results of rapid urease test (CLO) and polymerase chain reaction (PCR) with gastric mucosal tissues after the study on therapeutic effects of H. pylori infection with Sanguisorba officinalis extract
Group Inoculationa n Positive reaction (positive percent) b
H. pylori Treatment CLO PCR
I Yes Sanguisorba 10 0∗ (0 %, CI c 0-25.9) 0∗ (0 %, CI 0-25.9)
II Yes PBS 10 10 (100 %, CI 74.1-100) 10 (100 %, CI 74.1-100)
III No Sanguisorba 10 0∗ (0 %, CI 0-25.9) 0∗ (0 %, CI 0-25.9)
IV No PBS 10 0∗ (0 %, CI 0-25.9) 0∗ (0 %, CI 0-25.9)

a Treatment was conducted daily during 2 weeks after H. pylori inoculation.

b The positive percent revealed H. pylori colonization, which was observed as red color change from yellow color medium.

c Incidence percentage (95% confidential interval; CI) was calculated with MiniTab statistic software program.

∗ Significantly different from the positive control group II (P<0.05).

TOOLS
Similar articles